SCHEMBL7206947

SCHEMBL7206947

CS(=O)(=O)Nc1ccc(Oc2ccc3c(c2)SCCO3)c(CN)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 9/20 0.71
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KCNH2 Q12809 1/20 0.39
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 3/20 0.33
MEN1 O00255 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207143 0.90 SLC6A4 (0.71) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL7206568 0.83 SLC6A4 (1.00) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL6151642 0.72 SLC6A4 (0.77) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL6151911 0.70 SLC6A4 (0.62) SLC6A4SLC6A2SLC6A3KCNH2GAA
SCHEMBL7207152 0.68 SLC6A4 (0.71) SLC6A4SLC6A2SLC6A3
SCHEMBL6153164 0.68 SLC6A4 (0.60) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL7211553 0.67 SLC6A4 (0.71) SLC6A4SLC6A2SLC6A3KCNH2LMNA
SCHEMBL18352140 0.65 KDM4E (0.47) KCNH2ALDH1A1LMNANPC1RAB9A
Formic Acid SCHEMBL6000205 0.65 PTGDR2 (0.37) SLC6A4KCNH2CTNNB1WNT3A
Formic Acid SCHEMBL6000196 0.65 SLC6A4 (0.53) SLC6A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610747-B2 Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder PFIZER INC. 2003-08-26 US disclosed
US-20030060456-A1 Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder PFIZER INC. 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060456-A1 Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder HTR6, HTR2C, SLC6A3 SLC6A4 5/4885SLC6A2 9/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.